BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-136@pharmaconomics
DTSTAMP:20260707T021809Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:INX Phase 2 — IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide (estimated date)
DESCRIPTION:Phase 2 trial results for IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide in Obstructive Sleep Apnea (OSA) are due ~ Apr 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT07635563\n\nTrack it: https://www.pharmaconomics.com/e/136
URL:https://www.pharmaconomics.com/e/136
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR